{
  "docId": "019de073-b144-743c-94c4-bc5a80eb44df",
  "docSlug": "9540d42c57dd536e8cb82c97bd211004",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 50 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 41,
  "pageCount": 50,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide highlights the lack of FDA-approved monthly IVR options for combined hormone therapy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-b144-743c-94c4-bc5a80eb44df/41",
  "deckHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df",
  "deckJsonHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df.json",
  "deckAnchorHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.63
      },
      "kind": "list",
      "text": "The 2022 Hormone Therapy Position Statement of The North American Menopause Society (NAMS), supports HT in peri-and post-menopausal women. NAMS observes: non-oral routes may offer advantages over oral routes of administration.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b64e8a39-bf29-40f7-8d3f-18cf81b795ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.45,
        "x": 0.21,
        "y": 0.31
      },
      "kind": "metric",
      "text": "Over 45M women in U.S. approaching or in menopause",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1f70742-cb0a-4347-bd7b-42778876c9b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "Combination bio-identical estradiol + bio-identical progesterone 28-day IVR for hormone therapy following menopause. There are no FDA approved options with both hormones in one monthly IVR.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7a8e721f-dc90-4b54-83b3-08d177c6546d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.88,
        "x": 0.06,
        "y": 0.53
      },
      "kind": "paragraph",
      "text": "Hormone Therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS) and genitourinary syndrome of menopause (GSM), and has been shown to prevent bone loss and fracture.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "898e3c85-1fa9-478a-8997-68d0655a9cb9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.98,
        "x": 0.01,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "*505(b)(2) candidate. 1. U.S. Census Bureau... 2. https://www.menopause.org/docs/default-source/professional/nams-2022-hormone-therapy-position-statement.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9df47e79-7665-4a7a-ad48-e7ab50d5fd4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.16,
        "x": 0.42,
        "y": 0.03
      },
      "kind": "title",
      "text": "DARE-HRT1*",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ed55f43-04c0-4cbb-b0e1-b9fa524807d9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}